In a report released today, Robert LeBoyer from Noble Financial maintained a Buy rating on Cadrenal Therapeutics, Inc. (CVKD – Research Report), with a price target of $4.00. The company’s shares closed yesterday at $0.58.
According to TipRanks, LeBoyer is an analyst with an average return of -10.9% and a 24.63% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as GeoVax Labs, Unicycive Therapeutics, and Cadrenal Therapeutics, Inc..
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cadrenal Therapeutics, Inc. with a $4.00 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $3.14 and a one-year low of $0.40. Currently, Cadrenal Therapeutics, Inc. has an average volume of 380.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cadrenal Therapeutics, Inc. (CVKD) Company Description:
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
Read More on CVKD:
